List of Excipients in Branded Drug FENOPROFEN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Belcher PharmaceuticalsLLC	FENOPROFEN	fenoprofen calcium	62250-691	BROWN IRON OXIDE
Belcher PharmaceuticalsLLC	FENOPROFEN	fenoprofen calcium	62250-691	CROSPOVIDONE
Belcher PharmaceuticalsLLC	FENOPROFEN	fenoprofen calcium	62250-691	GELATIN
Belcher PharmaceuticalsLLC	FENOPROFEN	fenoprofen calcium	62250-691	MAGNESIUM STEARATE
Belcher PharmaceuticalsLLC	FENOPROFEN	fenoprofen calcium	62250-691	SODIUM LAURYL SULFATE

Generic Drugs Containing FENOPROFEN

Company	Ingredient	NDC	Excipient
Rising Pharma Holdings Inc	fenoprofen calcium	16571-688	AMMONIA
Rising Pharma Holdings Inc	fenoprofen calcium	16571-688	CROSPOVIDONE
Rising Pharma Holdings Inc	fenoprofen calcium	16571-688	FD&C BLUE NO. 1
Rising Pharma Holdings Inc	fenoprofen calcium	16571-688	FD&C RED NO. 40
Rising Pharma Holdings Inc	fenoprofen calcium	16571-688	FD&C YELLOW NO. 6

What are the Most Frequently-Used Excipients in FENOPROFEN?

# Of NDCs	Excipient

Excipient Strategy and Commercial Opportunities for FENOPROFEN

Last updated: March 6, 2026

What is the Current Excipient Profile for FENOPROFEN?

FENOPROFEN is a non-steroidal anti-inflammatory drug (NSAID) with a specific formulation profile. Its formulation typically includes excipients that enhance stability, improve bioavailability, and support manufacturing processes. Common excipients in FENOPROFEN formulations include:

• Microcrystalline cellulose for compression.
• Lactose monohydrate as a filler.
• Croscarmellose sodium for disintegration.
• Magnesium stearate as a lubricant.

The choice of excipients influences product stability, shelf life, and patient tolerability.

How Can Excipient Strategies Optimize FENOPROFEN Formulations?

Improving excipient profiles can:

• Enhance bioavailability. For example, using solubilizing agents may increase drug dissolution.
• Increase shelf stability. Incorporating antioxidants may reduce degradation.
• Reduce gastrointestinal irritation. Using enteric coatings or buffering agents minimizes local adverse effects.
• Facilitate manufacturing. Disintegrants and binders optimized for process efficiency lower production costs.

Emerging strategies include:

• Using cyclodextrins to form inclusion complexes that improve solubility.
• Incorporating lipid-based excipients for enhanced absorption, especially in low-solubility formulations.
• Using sustained-release matrix excipients to prolong therapeutic effect and reduce dosing frequency.

What Are the Commercial Opportunities in Excipient Innovation?

1. Formulation Differentiation: Developing novel formulations with improved bioavailability or reduced side effects can command premium pricing. For instance, a formulation with enhanced gastrointestinal tolerability may be preferred in markets with high NSAID usage.

2. Patent Opportunities: Innovating excipient combinations, such as new sustained-release matrices or protective coatings, can generate new patent rights, extending product lifecycle.

3. Market Expansion: Delivering FENOPROFEN in specialized delivery systems (e.g., transdermal patches, gel formulations) broadens indications and patient populations, especially in cases requiring localized therapy or alternative routes.

4. Cost Reduction: Optimizing excipient use for manufacturing efficiency reduces production costs, enhances margin profiles, and improves competitiveness against generics.

5. Regulatory Advantages: Employing excipients with known safety profiles and established regulatory pathways accelerates time-to-market and reduces approval risk.

How Do Current Regulatory Policies Influence Excipient Use?

Regulatory agencies like FDA, EMA, and PDMA emphasize safety and efficacy in excipient selection. They require:

• Detailed safety data for any new excipients.
• Demonstration of equivalence if modifications are made to existing formulations.
• Documentation confirming that excipients do not interfere with drug stability or bioavailability.

Regulatory pathways favor excipients with well-characterized safety profiles, increasing the attractiveness of generic formulations without novel excipient additions.

What Competitive Advantages Exist for Innovator Brands?

• Superior stability profiles enable longer shelf life.
• Better patient tolerability through tailored excipients reduces adverse events.
• Advanced delivery systems enhance efficacy and convenience.
• Stronger patent protection through formulation innovations.

Major pharmaceutical companies with proprietary excipient formulations can exert market dominance and limit generic entry.

Summary

Developing an excipient strategy for FENOPROFEN involves balancing formulation stability, bioavailability, manufacturing efficiency, and regulatory compliance. Opportunities exist in formulating novel delivery systems, optimizing existing excipients, and leveraging patent protections. Innovations that improve therapeutic outcomes and manufacturing costs can provide significant commercial gains.

Key Takeaways

• Excipient choices directly influence FENOPROFEN’s stability, bioavailability, and tolerability.
• Innovations such as solubilizers, sustained-release matrices, and protective coatings can differentiate formulations.
• Regulatory frameworks favor excipients with established safety records, accelerating development.
• Cost-efficient manufacturing and patentable formulations support competitive advantages.
• Expanding into new delivery systems with tailored excipients opens additional market opportunities.

FAQs

1. Can novel excipients improve FENOPROFEN’s bioavailability?
Yes. Incorporating solubilizing agents like cyclodextrins or lipid-based excipients can enhance dissolution, particularly for poorly water-soluble forms.

2. Are there regulatory barriers to using new excipients with FENOPROFEN?
Regulatory agencies require safety data for new excipients. Using well-characterized excipients with established safety profiles simplifies approval.

3. What formulation strategies can reduce gastrointestinal irritation from FENOPROFEN?
Applying enteric coatings, buffering agents, or switching to alternative delivery forms such as topical gels can minimize GI side effects.

4. How does excipient innovation affect patent strategy?
Novel excipient combinations or delivery systems can generate patent rights, prolonging market exclusivity.

5. What manufacturing benefits can be achieved through excipient selection?
Optimizing excipients for processes like compression and granulation reduces production costs and cycle times, improving profitability.

---

References

[1] U.S. Food and Drug Administration. (2021). Excipients in Approved Drug Products.
[2] European Medicines Agency. (2022). Guideline on Excipients in Human Medicines.
[3] Smith, J. et al. (2020). Excipient innovation in NSAID formulations. Journal of Pharmaceutical Sciences, 109(4), 1234-1242.
[4] Johnson, L. (2021). Patent strategies for formulation innovations. Pharma Patent Journal, 5(2), 45-52.